bioAffinity Technologies, Inc. announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster showcasing successful identification of Stage 1A lung cancer using CyPath® Lung.
CyPath® Lung provided clarity and actionable results in complex cases, aiding in confirmed diagnoses at early stages.
NLCRT annual meeting to feature Dr. Downie's presentation on December 8, 2025, at Grand Hyatt Atlanta in Buckhead.
High Sensitivity
CyPath® Lung showed 92% sensitivity in detecting lung cancer in high-risk patients with small nodules.
Specificity & Accuracy
The test demonstrated 87% specificity and 88% accuracy, crucial for early detection and treatment planning.
Noninvasive Approach
CyPath® Lung's noninvasive sputum-based flow cytometry test is a valuable tool in diagnosing lung cancer at early, treatable stages.
- CyPath® Lung addresses the clinical burden of uncertain pulmonary nodules by providing clarity and guidance in diagnosis.
- Incorporating CyPath® Lung into diagnostic pathways can lead to accelerated diagnosis, improved patient outcomes, and reduced risks of invasive procedures.
The successful cases presented by Dr. Downie highlight the importance of innovative diagnostic tools like CyPath® Lung in improving patient care and outcomes in the fight against lung cancer.